… Anaplastic thyroid cancer, one of the most aggressive and rapidly fatal cancers, represents
the least common form of thyroid cancer at approximately 2% of all thyroid malignancies [6], [7…

… agents for the treatment of differentiated and medullary thyroid cancers being studied at this
… on systemic treatments for patients with radioactive iodine–resistant thyroid cancer that has …

… In the future, with further knowledge of molecular mechanisms and research, we will have
more and more effective options available for treating metastatic/refractory thyroid cancers. …

… RAI treatment is the first-line systemic treatment in patients with advanced disease [4]. …
RAI treatments are young patients with small metastases from well-differentiated thyroid cancer …

… work-up before treatment is started is crucial to appropriately tailor treatment. In this Seminar…
treatment of thyroid nodules and thyroid cancer, and discuss cutting-edge treatments that …

… The role of newer systemic agents has been … Cancer Network guidelines in the treatment
of thyroid cancer, published in March 2019. Molecular testing can guide systemic treatment with …

… Based on the GLOBOCAN 2020 database of cancer incidence and mortality by the WHO
International Agency for Research on Cancer, thyroid cancer has the ninth highest cancer …

… Patients with differentiated thyroid carcinoma have an excellent prognosis. The multimodal
… to achieve optimal treatment of differentiated thyroid cancer (DTC) and to minimize treatment-…

… Dabrafenib plus trametinib is the only approved treatment by FDA for BRAF … future treatments
of thyroid cancer with regards to the advanced and progressive cases that require systemic …

… For several decades before the development of targeted therapies, chemotherapy was
the only systemic treatment available for thyroid cancers. The scarcity of advanced …